Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Viridian Therapeutics has received an average recommendation of "Moderate Buy" from ten analysts, with one holding and nine buy ratings.
• The average one-year price target for the stock is approximately $37.78, reflecting optimism among analysts regarding its future performance.
• Viridian's latest earnings report indicated an EPS of ($1.00), meeting analyst estimates, with revenue exceeding expectations at $0.08 million.

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the ten analysts that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $37.7778.

A number of equities research analysts have weighed in on the company. Wells Fargo & Company reduced their target price on Viridian Therapeutics from $27.00 to $26.00 and set an "equal weight" rating on the stock in a report on Thursday, August 7th. Jefferies Financial Group assumed coverage on shares of Viridian Therapeutics in a research report on Monday, August 25th. They issued a "buy" rating and a $44.00 target price for the company. Royal Bank Of Canada lowered their price target on Viridian Therapeutics from $45.00 to $41.00 and set an "outperform" rating on the stock in a report on Thursday, August 7th. Oppenheimer upped their price target on shares of Viridian Therapeutics from $28.00 to $32.00 and gave the stock an "outperform" rating in a research report on Thursday, August 7th. Finally, The Goldman Sachs Group lifted their target price on shares of Viridian Therapeutics from $27.00 to $30.00 and gave the stock a "buy" rating in a research note on Thursday, August 7th.

Viridian Therapeutics Trading Up 0.6%

Shares of NASDAQ:VRDN traded up $0.12 during midday trading on Friday, reaching $19.55. The company had a trading volume of 607,223 shares, compared to its average volume of 887,679. The company has a fifty day simple moving average of $18.06 and a two-hundred day simple moving average of $15.48. The firm has a market cap of $1.60 billion, a price-to-earnings ratio of -5.10 and a beta of 0.53. The company has a debt-to-equity ratio of 0.04, a quick ratio of 11.01 and a current ratio of 11.01. Viridian Therapeutics has a 1-year low of $9.90 and a 1-year high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($1.00) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($1.00). The firm had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.05 million. Viridian Therapeutics had a negative return on equity of 78.95% and a negative net margin of 112,806.88%.The company's revenue was up 4.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.81) EPS. Research analysts predict that Viridian Therapeutics will post -4.03 earnings per share for the current year.

Institutional Trading of Viridian Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of VRDN. Amalgamated Bank boosted its stake in Viridian Therapeutics by 49.7% during the 1st quarter. Amalgamated Bank now owns 2,531 shares of the company's stock valued at $34,000 after purchasing an additional 840 shares during the period. GAMMA Investing LLC grew its holdings in shares of Viridian Therapeutics by 3,892.9% during the first quarter. GAMMA Investing LLC now owns 8,425 shares of the company's stock worth $114,000 after buying an additional 8,214 shares in the last quarter. Sei Investments Co. bought a new position in shares of Viridian Therapeutics in the 2nd quarter valued at about $147,000. Y Intercept Hong Kong Ltd bought a new position in Viridian Therapeutics during the second quarter worth about $170,000. Finally, Creative Planning bought a new stake in shares of Viridian Therapeutics during the second quarter worth $179,000.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.